TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Life Sciences

    Translating Aging

    On Translating Aging, we talk with the worldwide community of researchers, entrepreneurs, and investors who are moving longevity science from the lab to the clinic. We bring you a commanding view of the entire field, in the words of the people and companies who are moving it forward today. The podcast is sponsored by BioAge labs, a clinical-stage biotechnology company developing therapies to extend human healthspan by targeting the molecular causes of aging.

    Advertise

    Copyright: © Copyright 2021 BioAge Labs

    • Apple Podcasts
    • Google Play
    • Spotify

    Latest Episodes:
    Bringing Talent into the Longevity Industry’s Workforce (Mark Hamalainen) May 18, 2022
    Show notes

    In today’s episode of Translating Aging, Chris welcomes Mark Hamalainen, the founder and director of LessDeath, to discuss how to encourage the influx of talents into the longevity field. LessDeath is an organization on a mission to support the growth and effectiveness of the longevity industry’s workforce. Today, Mark shares with us his experience in the longevity space, why he founded LessDeath, and what to expect at the upcoming LessDeath Longevity Summer Camp.

    Noting that his experience in the longevity space was propelled by his fascination as a teenager, Mark goes on to share details about leaving his Ph.D. program to get hands-on experience in the longevity world and discover the many talents represented in the industry. He speaks about founding LessDeath, what the organization hopes to achieve, the inaugural LessDeath Longevity Summer Camp and the gap this event is hoping to bridge in the industry. Included in this episode are interviews with Stephanie Dainow and Kia Winslow, camp counselors for the Longevity Summer Camp, in which they share the kinds of talent they expect to attract to the event and the kinds of activities that will take place.

    Episode Highlights:

    • How Mark got involved in the longevity space
    • The biggest issue in the longevity field
    • The different talents prospering in the biotech field
    • Why gene delivery and gene therapy require more technological development
    • The challenges with getting people into the longevity biotech field
    • How LessDeath tackles the talent issue and encourages networking
    • The LessDeath Longevity Summer Camp
    • Interview with Stephanie Dainow
    • How Stephanie got into the longevity space
    • Interview with Kia Winslow
    • Kia’s story of getting into biotech
    • What is next for LessDeath?

    Quotes:

    “I started a Ph.D. at Cambridge working on some gene therapy development. But I quickly got a bit disillusioned with the pace and the amount of extra work involved in grant writing, bureaucracy, and academia.”

    “A lot of people would prefer to work on important problems like longevity, climate change, building a multiplanetary species. But it can be difficult to know where to start, and how to build a sustainable career out of it.”

    “I've never liked the idea of getting older and losing my faculties and physical capabilities.”

    “If you want to invest your time supporting initiatives that drive measurable improvement to the human condition, but you're really not sure where to start, this is the event for you.”

    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    LessDeath Website LessDeath.Org

    Apply for LessDeath Longevity Summer Camp

    Mark’s LinkedIn


    VitaDAO - Democratizing Longevity Research through the Blockchain (Tyler Golato and Laurence Ion) May 04, 2022
    Show notes

    On today’s episode of Translating Aging, Chris welcomes Tyler Golato and Laurence Ion to talk about VitaDAO, a collective accelerating research in human longevity and decentralized drug development. The pair start the conversation off by discussing their company’s roots - a previous business venture that sought to change the incentive structures around drug development. VitaDAO was created as a means to support biological longevity research through decentralized means.

    They go on to discuss VitaDAO’s future, how they can increase liquidity, and their goals to advance drug development. Golato and Ion argue that the present is a perfect time to create VitaDAO, given the current intersection between biotech, block chain, and longevity research. They conclude by recalling the early-life dreams that inspired them to enter this field.

    Episode Highlights:

    • The essence of VitaDAO
    • Changing the incentive structures around drug development
    • The partners’ passion for longevity
    • VitaDAO’s decentralized structure
    • Project sourcing and funding
    • Increasing liquidity
    • Goals to end drug development
    • The intersection of biotech, block chain, and longevity
    • Why Tyler and Laurence are interested in longevity

    Quotes:

    “VitaDAO was born out of an early concept that we had been working on at a company called Molecule, which is a company that I co-founded about three years ago with a vision of doing decentralized drug development.”

    “It's not completely open, completely decentralized to the point where it's paralyzing for the organization, but we try to look at the things that are most valuable to decentralize in order to make the organization as maximally efficient as possible.”

    “We really try to make it as easy as possible for token holders to make informed decisions about whether or not something is ultimately worth funding. We like to do so once we're at the point where we ensure that we can actually progress with a deal.”

    “We are distinctly different from a venture fund in terms of our endpoint is not really ROI impact, it's really impact in the space. And that comes in many different forms, in terms of taking a diversified approach to funding longevity research.”

    “Even if we spin out a NewCo, these contributors can vote on what projects are funded, how they are spun out, and then they can co-invest and help these therapeutics eventually come to market.”

    “In the long term, we really hope to be able to do a lot of things within the decentralized science ecosystem as the space broadens and has liquidity to do so through partnerships with organizations like Molecule and LabDAO.”

    “Certain things like clinical trials don't yet have a business model. So we can create one by having either philanthropic groups, patient groups or even a government/life insurance company that has an economic incentive to improve health outcomes.”

    “Crypto has long been dismissed by the incumbents.”

    “People who are really looking at how technology and innovation can drive humanity forward and drive the way that we govern.”

    “What problem is more interesting than human aging? I mean, for me, it's so philosophical; it's so poetic.”


    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    VitaDAO Homepage


    Building Community in the Longevity Biotech Space (Nathan Cheng) Apr 06, 2022
    Show notes

    On today’s episode of Translating Aging, Chris welcomes Nathan Cheng, the program director at On Deck Longevity Biotech (ODLB), to discuss how ODLB is cultivating new founders and connecting people in the longevity biotech space. Nathan writes about the longevity biotech industry in his Longevity Marketcap Newsletter, is the founder of Longevity List which aims to connect job seekers, companies and investors in the longevity industry, and is on a self-professed mission to end biological aging, Today, he tells us about the purpose of ODLB, its achievements thus far, and the bridge it hopes to build in the longevity biotech industry.

    Nathan begins the conversation by discussing what On Deck is and why the company was formed. He briefly narrates his journey in tech, what increased his interest in the longevity space, and the mission of the ODLB, as well as how the fellowship works towards creating founders. He goes on to discuss the obstacles many face when they get accepted in the fellowship and how ODLB works to reduce those obstacles by promoting face-to-face interactions. Also contained in this episode are brief interviews with ODLB fellows Brian Hodge and Gabe Warshauer-Baker.

    Episode Highlights:

    • What is On Deck?
    • Nathan’s journey in the longevity space
    • On Deck Longevity Biotech’s (ODLB) mission
    • The importance of connecting those in the longevity biotech space
    • How mentors contribute in ODLB
    • Does the startup culture reward extroverts over introverts?
    • Getting into the ODLB fellowship
    • Interviews with ODLB fellows
    • Feats the ODLB has achieved
    • The future of the longevity biotech space

    Quotes:

    “At a high level, On Deck is where people come to start and accelerate their companies. It's also a place where people start and accelerate their careers in the startup economy.”

    “What makes On Deck unique is that it's a huge network of interconnected program communities. So we have communities centered around specific career goals.”

    “ODLB’s mission is to increase the number of people working to build longevity biotech startups.”

    “For some people coming from the scientific domain, this whole idea of networking is foreign to them or nebulous.”

    “We're gonna generate new founders, but among the people who decide for whatever reason not to become founders, we also want them to be encouraged and empowered to be involved in longevity biotech in some other capacity.”

    “Putting ourselves on the map for people who are interested in building longevity biotech, I think that is our greatest achievement so far. ”

    “So I think just more efforts in popularizing this geroscience paradigm, you know, actually targeting aging, I think there's a lot to be done there as well.”

    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    On Deck Longevity Biotech Website

    Nathan Cheng Twitter



    Aging Goes to Washington! — The Alliance for Longevity Initiatives (Sonia Arrison and Dylan Livingston) Mar 23, 2022
    Show notes

    In today's episode, Chris is joined by two leaders of the Alliance for Longevity Initiatives, A4LI, the first and only 501(c)(4) nonprofit organization founded with the goal of creating social and political action around the issues of combating age-related chronic conditions and increasing our number of healthy, disease-free years. Sonia Arrison is a best-selling author, analyst, entrepreneur, and investor who is founder of 100 Plus Capital, Chair of the Alliance for Longevity Initiatives, co-founder of Unsugarcoat Media (acquired by Medium), and an associate founder of Singularity University. Dylan Livingston, the founder and president of A4LI, has a background in political organizing at the state and national levels.

    The conversation begins with our guests reviewing their journey to the world of longevity science and ultimately A4LI. They then explore many aspects of their organization including the needs it will address, the obstacles it will encounter and how it will overcome them, and its plan for succeeding in its mission. They go on to share what they have already accomplished, their ties on both sides of the aisle in Congress, Silicon Valley's current perspective on their work, and how listeners can help them achieve their mission. Drawing the episode to a close, Sonia and Dylan share their vision for what success would look like for A4LI five years down the road.


    In this episode, you will learn about the need for an organization such as A4LI to create social and political action around age-related conditions, and how our guests plan to fill this need both now and into the future.


    Episode Highlights:


    • Sonia and Dylan's journey to the area of longevity and longevity science
    • How they both came to be involved with A4LI
    • The unmet needs that A4LI will address
    • The obstacles it will meet in pursuing its mission and how it will overcome them
    • The sense in which biology of aging is underfunded
    • A4LI's plan for succeeding in its mission
    • The Regenerative Medicine Advanced Therapy designation
    • What it has accomplished already
    • The ties it has made with both Democrats and Republicans
    • Silicon Valley's perspective on their work
    • How researchers, entrepreneurs, and investors can help A4LI
    • Sonia and Dylan's vision of success for A4LI in 5 years


    Quotes:

    “Sonia has been intimately involved since the organization's inception. And I'm really happy that she is able to be the chair of the board because her leadership and guidance has been absolutely crucial.”

    “Essentially A4LI will be establishing a line of communication between the longevity industry and elected officials.”

    “There's a lot of longevity companies out there who are doing some really cool things that are going to extend our health spans. And, and so we need to make sure that the atmosphere is right for that.”

    “We look to kind of educate, you know, not only politicians, but also the voting public on what's possible.”

    “What we're saying here is, what I hear you saying is, it should be okay for a company to say we're a longevity company.”

    “You'd think that the government would want to fund that more, and they should, because of the e massive impact that a drug that treats aging could have.”

    “Even if funding is coming in from the private sector, biotech companies still stand to gain from formalized efforts, because they're going to get a smoother regulatory environment and potentially greater legitimacy for the products and ideas that they're developing. “

    “By simply doing what other advocacy efforts do - that is public persuasion campaigns, their advertising - I think we can really open some ears up and get people focused on this space a little more.”

    “One of the things that was really important to me about getting involved in this is that it remained bipartisan, and so far, we've managed to do a really good job of having people on both sides of the aisle.”

    “I think people in Silicon Valley are interested and excited, and are just sort of waiting to see what's going to happen, and, you know, just how interested Congress might be.”

    “Everything is going to change with the introduction of an effective longevity drug. So, you know, we need to help the government and institutions prepare for that.”

    “Once somebody starts stealing your idea, you know that it's gold.”

    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    A4LI Homepage


    Measuring Biological Age (Dr. Morgan Levine) Mar 09, 2022
    Show notes

    Today’s guest is Dr. Morgan Levine, an assistant professor of Pathology and Epidemiology at Yale School of Medicine. She is also a Founding Principal Investigator at Altos, a new biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience. Dr. Levine shares her expertise on biological aging, aging clocks, cellular reprogramming, and a peek into the research she’s currently undertaking at Altos here today.

    She starts the conversation by explaining the differences between biological aging and chronological aging. She then delves into topics surrounding biological clocks such as DNA methylation, and discusses her work at Altos and how this will differ from an academic environment. Dr. Levine finishes up by highlighting what Altos hopes to bring to science and biotech in years to come.

    In today’s episode, you’ll learn the difference between biological and chronological aging, the nature of biological clocks, and some of the exciting work taking place in biotechnology these days.

    Episode Highlights:

    • The difference between chronological aging and biological aging
    • What is an epigenome?
    • How DNA methylation is measured
    • Using aging clocks for a particular demographics
    • How to decide if a discovery slows the biological clock
    • Applications of clocks as it pertains to aging and longevity
    • The costs of individual measurements
    • Dr. Morgan’s work at Altos
    • How Altos was founded
    • Deciding the direction of research
    • Understanding cellular reprogramming
    • The future at Altos

    Quotes:

    “Age measured in chronological time was the biggest risk factor for most diseases.”

    “I like to think of the epigenome as almost the operating system of a cell.”

    “The things that we assume should affect aging, in potentially an animal model, show effects when using the epigenetic clock.”

    “We've actually taken the human epigenetic clock and broken them out into.. what we would call different modules.”

    “If we're measuring biological age, it should first correlate with chronological age to some degree, but not perfectly.”

    “We’ve become much more interested in understanding the clocks rather than developing new clocks… What’s driving the changes that are captured by the clocks, and how do those link to the outcomes they’re associated with?”

    “My lab is really a combination of both experimental wet lab people and computational dry lab people.”

    “I think saying we just work on aging, or just work on longevity, is really constraining us to some degree.”

    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    Dr. Morgan’s LinkedIn

    Altos Labs Website



    Stem Cell Biology and Longevity Research with Dr. Thomas Rando Feb 23, 2022
    Show notes

    Today’s guest is Dr. Thomas Rando, Professor, Neurology; Molecular, Cell and Developmental Biology, and a pioneer in stem cell biology and the biology of aging. Dr. Rando is the Director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles, and the co-founder and Chair of the Board of Directors at Fountain Therapeutics. In today’s episode, he shares information surrounding cell cycle, parabiosis, and replacement therapy.

    Dr. Rando begins by explaining why the cell cycle is important and the place of aging cells in the world of cell cycle. He explains the quiescent states of cells and how heterochronic parabiosis has been tested on animals to determine if cells in a younger animal can be used to activate those in an older animal. He also discusses how three factors impact aging: genetics, diet, and exercise.

    In this episode, you’ll learn the meaning and importance of cell cycle and parabiosis and how they both relate to aging.

    Episode Highlights:

    • Dr. Rando’s transition from neurology to stem cell biology
    • The importance of cell cycle
    • Why aging cells do not repair tissues
    • Exploring the quiescent state
    • How heterochronic parabiosis works
    • Chronic inflammation in older people
    • Does exercise benefit the tissues in the body?
    • The connection between exercise and replacement therapy
    • The relation between diet and longevity
    • What are ketogenic diets?
    • Dr. Rando’s thoughts on supplementation
    • The future of stem cell therapy
    • Can bone marrow be used to rejuvenate older people?
    • Can stem cell therapy treat Alzheimer's disease?
    • Transitioning from an academic to a founder


    Quotes:

    “Why is it that we heal our injuries and wounds less well as we age?”

    “The older we get, the more difficult it is to activate these cells out of that state. And you can imagine that if a cell is dormant, and you can't wake it up, it's not going to do very well in terms of repairing tissues.”

    “There's no free lunch here. What benefits the old animal hurts the young animal.”

    “The only reason why a species survives and thrives and continues is because of reproduction.”

    “No one wants to calorically restrict for their whole life. I mean, no one wants to go through their life eating 30%.”

    “Anything that we can do to find a healthy diet that is palatable and sustainable, and prevents obesity will be a good thing.”

    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    Fountain Therapeutics





    Cellular senescence in aging and disease (Dr. Marco Demaria) Feb 09, 2022
    Show notes

    Dr. Marco Demaria is an Associate Professor in Cellular Ageing at the Medical Faculty of the University of Groningen. In 2018, he co-founded a start-up company, Cleara Biotech, devoted to developing anti-senescence drugs. Today, Dr. Demaria shares his insights and research on how senescence promotes aging and factors that promote the creation of senescent cells.

    In this episode, Dr. Demaria explains what cellular senescence means and discusses the good and bad that comes with having senescent cells in the body. He explains the role of senolytics in combating senescent cells and how senescent cells could be the cause of the severity of COVID in older people.

    In this episode, you’ll learn how senescent cells contribute to aging, the evolution of the senescent field, some current studies in the field, and what Dr. Demaria hopes to see in the field in years to come.

    Episode Highlights:

    • What is cellular senescence?
    • The positive and negative sides of senescent cells
    • The role of senescent cells in aging
    • What is the heterogeneity of senescence?
    • Using senolytic drugs to eliminate senescent cells
    • How does hypoxia affect senescent cells?
    • The relation between senescence and COVID in the elderly
    • Dr. Demaria’s progress in his study and work at Cleara Biotech
    • The evolution of the senescence field in the past 12 years
    • Experiments Dr. Demaria would like to see done

    Quotes:

    “A cell that is in an early senescence state seems to be different from a senescence cell in a late state.”

    “The next generation of senolytic drugs should definitely focus on dissecting the targets that they want to reach, because of the potential side effect of administering a general senolytic that could interfere with beneficial senescence.”

    “What we call senolytic drugs and compounds are mostly repurposed drugs.”

    “We also want to make this study of stem cell longevity in mice and in mouse tissues, because we think that might be another mechanism by which we can improve health, which is maintaining the stem cell pool because we retard the aging of the stem cells.”

    “There are two prominent senescence groups that are now using senolytics in the clinic for COVID-19 patients.”

    “There is no magic bullet so far that we have found but just because we haven't probably combined the right interventions at the right moment in the right context.”

    “The experiments I would like to see done are to combine approaches that target different aspects of aging.”

    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    Cleara Biotech Website


    The TAME trial and beyond (Dr. Nir Barzilai — AECOM) Jan 26, 2022
    Show notes

    The TAME trial and beyond (Dr. Nir Barzilai)

    Dr. Nir Barzilai is the founding director of the Institute for Aging Research, the Nathan Shock Center of Excellence in the Basic Biology of Aging, and the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine of Yeshiva University. He is also the author of the book Age Later. Today, Dr. Nir brings his expertise to the podcast for a discussion regarding longevity and aging.

    Nir starts the conversation with a discussion on the existing regulatory frameworks that create impediments to the longevity biotech sector such as the FDA regulations. He also explores the use of metformin in combating age-related diseases, the clinical trials surrounding metformin being carried out in the Longevity Biotech Association, dealing with members of the government, and his perspective regarding what longevity biotech will be like in 5 years.

    In this episode, you’ll learn the uses of metformin and its relation to age-related diseases and what Nir hopes to see in the longevity industry in years to come .

    Episode Highlights:

    • The existing regulatory frameworks that create impediments to the longevity biotech sector
    • What is metformin and its relationship with age-related disease?
    • Targeting aging with metformin — the TAME trial
    • How other biomarkers would be tracked in the study
    • The future of the trials and what is set to happen after it ends
    • Examining the economics
    • The mission of the Longevity Biotech Association
    • The longevity industry in 5 years
    • Challenges that come with conversing with the Government concerning longevity and aging

    Quotes:

    “Aging drives diseases and those diseases can be delayed.”

    “If aging drives all diseases, then it's the mother of diseases.”

    “After all, what are we trying to do? We are trying to prevent a cluster of age related diseases.”

    “Even if metformin doubles in price because of demand, it's still going to be the cheapest drug in the pharmacy.”

    “There are nine studies that show that people on metformin had less hospitalization, and less mortality from COVID if they were on metformin.”

    “Science is not a bipartisan issue.”

    “We need to extend the field and extend the actual funding to do it.”

    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    Dr. Nir Barzilai’s Twitter


    Natural history & the evolution of aging (Professor Steven Austad — University of Alabama) Jan 12, 2022
    Show notes

    Professor Steven Austad is a distinguished researcher in geroscience and the Protective Life Endowed Chair in Healthy Aging at the University of Alabama at Birmingham. He's also the Director of the Nathan Shock Center at UAB and the Senior Scientific Director of the American Federation for Aging Research.

    Today, Professor Austad joins Bob Hughes to discuss the biology of aging. He begins by narrating the discovery that sparked his interest in aging and his transition from animal behavior to the biology of aging. He discusses how these discoveries led him to the rate of living theory—the idea that the rate of aging is determined by your metabolic rate—and explains a somewhat paradoxical aspect to this theory: the hummingbird, which has a high metabolic rate, is relatively long-lived. He goes on to review evolutionary ideas to understand the rate of living theory, shares his striking discovery about how possums age more slowly in the absence of predation, and describes both why birds of flight live longer than terrestrial birds and the unusually long lifespan of bats.

    Professor Austad talks of how natural history observations can accelerate more molecular and pharmacologic insights into human health, explaining, “Evolution is smarter than you.” He shares his perspective of the research enterprise: what we do well, what we don't do well, and how we can be better. He also details where he stands on aging in the private sector and for-profit aging companies, the mechanisms of age-related decline, and gives details about his bet with Jay Olshansky about a 150-year-old person being alive by 2150. Finally, Professor Austad reveals his expectations on whether more people will live to be more than 120 or 150 in the second half of the century due to interventions, and shares what he would focus on if he was given $1 billion.

    In this episode, you'll learn about aging in animals and humans and the factors that determine their longevity. You also hear about aging in the private sector as well as comparing today's interventions to aging with evolutionary stimulus.

    Episode Highlights:

    • Professor Austad's transition from animal behavior to aging
    • The striking differences in aging between a South American species of opossums and mice
    • The rate of living theory
    • The constant heartbeat theory—understanding the impact of heartbeat rate and longevity
    • An alternative to the rate of living theory—the evolutionary approach
    • Professor Austad's study and discovery on the aging of possums without predator interference
    • Why birds of flight live longer than terrestrial birds
    • Current estimates on bat longevity and why bats have a long lifespan
    • How natural history observations can accelerate more molecular or pharmacologic insights into human health
    • How evolution is smarter than humans
    • Professor Austad's view of the research enterprise
    • Aging in the private sector and for-profit aging companies
    • Mechanisms in age-related decline
    • Professor Austad's bet with Jay Olshansky about a living 150-year-old person by 2150.


    Quotes:

    "The interesting thing is that project was about the sex ratio of the pups and was eventually published in Nature. And by the time it came out, I totally lost interest in that project, and I was off studying aging."

    "Evolution has this wonderful capacity to take a single-cell fertilized egg and have it develop into a healthy adult in some kind of species. It would seem to be just much easier to simply maintain that healthy adult once you have it, but yet it's almost ubiquitous that when aging occurs, that healthy adult gradually loses its health."

    "One of the evolutionary ideas to understand that was that evolution is all about reproduction, and what evolution will favor is whatever physiology maximizes reproductive rate."

    "One of the things about possums that's important to note is that about 80% of them are ultimately killed by predators."

    "So it's clear that the lack of predators had really had an impact on those opossums because they were just like the animals of the Galapagos, completely unafraid of humans."

    "The longest-lived wild bat is reported to be 41 years. And that's an animal that's about a fifth the size of a mouse."

    "High-frequency hearing is one of the first things we lose, but bats have to maintain that year after year after year because getting their food depends on it. They find their animals in the dark by screaming and listening for the echoes. So the fact that a bat can live over 40 years in the wild strikes me as much more impressive than if it lived 60 years in a cave somewhere."

    "One of my favorite quotes is that evolution is smarter than you are. I think that's true because it's just so long to experiment. And so I think evolution will have come up with solutions to, let's say, how to maintain muscles better, maintain vision longer, or maintain nerves better in some species than we currently already do in humans."

    "I think scientists are increasingly conservative because they want to be able to do something that they know works. And most people I know have at least half of their next grant proposal already done, half the research done before submitting the proposal. And that, to me, is a good recipe for incremental advances, but not a recipe for major breakthroughs."

    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    Professor Steven Austad LinkedIn

    Professor Steven Austad Wikipedia



    Personalized cell therapies at scale (Dr. Nabiha Saklayen — Cellino) Dec 15, 2021
    Show notes

    Dr. Nabiha Saklayen is CEO & co-founder of Cellino, a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies. Cellino’s proprietary technology aims to make personalized stem cell-derived therapies scalable for the first time. Dr. Saklayen received her Ph.D. in Physics from Harvard University as a Howard Hughes Medical Institute (HHMI) International Fellow.

    In this episode, she joins Chris Patil to discuss autologous cell therapy and the strides Cellino has made in cell therapy using Machine Learning and laser technology. Dr. Saklayen talks about the challenges that come with autologous cell therapy, particularly in the manufacturing and cost aspect, and how Cellino infuses automation to make this procedure easier. She discusses how machine learning is integrated in the whole process and gives a brief insight into her career as a physicist and founding Cellino. She rounds up by discussing the future of Cellino and how Cellino strives to provide solutions in cell therapy that would change the world one patient at a time and at low cost.

    In this episode, you’ll learn what cell therapy is and how Dr. Saklayen, through Cellino, is reshaping the world of cell therapy and biotech as we know it.

    Episode Highlights:

    ● What is cell therapy?

    ● Defining autologous cell therapies

    ● Examining the challenges with autologous cell therapy

    ● Cellino as a thought leader in the biotech industry

    ● The power of automation and laser therapy

    ● How machine learning contributes

    ● Dr. Saklayen’s career journey

    ● Going from a blood cell to a stem cell - Sendai virus and episomal vectors

    ● How to determine the success of an IPSC induction

    ● The future of Cellino

    ● Targeting diseases of aging

    ● How Cellino is providing solutions in aging aspects

    ● Cell therapies over small molecules

    ● Cellino’s goal for the next five years

    Quotes:

    “Cell therapy is a therapy where you make new cells for the patient and transplant them into the body to change the outcome of a disease or trajectory of a disease.”

    “It's about throughput. It's about yield. It's about consistency.”

    “The way we automate this process is by using machine learning algorithms that have been trained to look at images of cells and tell us which cells are high quality and which cells are not.”

    “It's really amazing to be able to tap into image-based machine learning algorithms and route the autonomous self-driving car industry towards advancing a lot of the neural nets that we're using in our training.”

    “I decided I want to be closer to real-world applications.”

    “Working together as an industry is going to be very important.”

    “Where we'd like to be in five years is we want to have our platform developed to a point where we can generate high quality patient specific cells in a reproducible manner, and do that for clinical doses.”

    Links:

    Email questions, comments, and feedback to podcast@bioagelabs.com

    Translating Aging on Twitter: @bioagepodcast

    BIOAGE Labs Website BIOAGELabs.com

    BIOAGE Labs Twitter @bioagelabs

    BIOAGE Labs LinkedIn

    Dr. Saklayen's TechCrunch Disrupt Talk

    Dr. Saklayen's LinkedIn


    Previous 1 3 4 5 6 7 Next

    Related Podcasts

    Science Friday

    1

    Science Friday Astronomy
    The Naked Scientists Podcast

    2

    The Naked Scientists Podcast Life Sciences
    Stuff To Blow Your Mind

    3

    Stuff To Blow Your Mind Life Sciences
    Stuff To Blow Your Mind

    4

    Stuff To Blow Your Mind Life Sciences
    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone

    5

    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone Health & Fitness
    All In The Mind

    6

    All In The Mind Government & Organizations
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights